ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned a consensus rating of “Moderate Buy” from the four ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $199.67.

Several analysts have commented on ICUI shares. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Finally, KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $153.20 on Friday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm’s fifty day simple moving average is $169.30 and its 200 day simple moving average is $152.42. The stock has a market cap of $3.75 billion, a P/E ratio of -33.52 and a beta of 0.62. ICU Medical has a twelve month low of $86.80 and a twelve month high of $196.26.

Insider Transactions at ICU Medical

In other news, COO Christian B. Voigtlander sold 1,962 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,364 shares of company stock valued at $6,869,878. 6.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. Innealta Capital LLC bought a new stake in shares of ICU Medical in the 2nd quarter valued at approximately $32,000. Hexagon Capital Partners LLC raised its holdings in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares during the period. Allworth Financial LP lifted its holdings in shares of ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 100 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in ICU Medical by 1,510.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in ICU Medical in the 2nd quarter worth about $70,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.